Google DeepMind Launches AlphaGenome 2 to Map DNA Changes in Cells
DeepMind's AlphaGenome 2 AI model deciphers how DNA alterations impact individual cells, opening new avenues for disease research and treatment.

Researchers at Google DeepMind have introduced AlphaGenome 2, an artificial‑intelligence system built to trace the effects of genetic variations at the cellular level. The model aims to provide scientists with a finer‑grained understanding of how changes in DNA manifest across different cell types, a challenge that has long hampered disease research.
AlphaGenome 2 follows its predecessor, expanding the scope of genetic‑cellular mapping and promising clearer clues about the biological roots of illness. By linking specific DNA mutations to cellular responses, the platform could help identify novel therapeutic targets.
The announcement, reported by The Verge AI, highlights the model’s potential to accelerate discovery in fields ranging from oncology to rare genetic disorders. While still in early stages, AlphaGenome 2 represents a significant step toward integrating AI with genomics to unravel complex disease pathways.
DeepMind emphasizes that the tool is designed for researchers, offering a more detailed view of a notoriously difficult problem. The hope is that this deeper insight will not only clarify disease mechanisms but also guide the development of new treatments.
As the scientific community begins to explore AlphaGenome 2’s capabilities, its impact on precision medicine and drug discovery will be closely watched.
Read also

Major US School Districts Weigh Leaving Google Search
New York, Los Angeles and Chicago school districts are exploring non‑Google search options after Google said disabling Gemini‑powered AI would also turn off Search.

Google Search Receives Gemini 4 Hydrogen Upgrade Worldwide
Google announced a global rollout of Gemini 4 Hydrogen for Search, aiming to deliver richer, more visual answers.

Anthropic Launches Nasdaq Debut, Shares Open at $111.50
Anthropic started trading on the Nasdaq under the ticker ANT, opening at $111.50 per share, a rise from its $83 IPO price.